Moderna Stock Jumps 6% as FDA Sets 2026 Decision Date for Flu Vaccine

Moderna (MRNA) shares jumped 6% following the U.S. Food and Drug Administration's (FDA) agreement to review its mRNA-based influenza vaccine. The regulatory agency is expected to issue its final decision by August 5, 2026, providing a concrete timeline for market participants. This move marks a significant reversal of the FDA's previous rejection and ends a public dispute over the vaccine's development path. Investors reacted favorably to the news, viewing the regulatory progress as a major milestone for the company’s product pipeline. Securing approval for this vaccine is critical for Moderna as it seeks to diversify its revenue streams beyond COVID-19 products. Market analysts suggest that the established decision date reduces regulatory uncertainty and strengthens the long-term outlook for the biotech firm.